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BACKGROUND. Desmoid tumor represents a rare monoclonal neoplasm arising
from deep musculoaponeurotic structures and may occur sporadically or in asso-
ciation with the familial adenomatous polyposis and Gardner syndromes. Desmoid
tumors do not appear to demonstrate metastatic potential; however, local infiltra-
tive growth results in significant morbidity and potential mortality. Although the
delineation of optimal therapy for desmoid tumors has been confounded by
several factors, surgical resection with adjuvant radiotherapy for a positive surgical
margin remains the standard approach. Responses have been demonstrated to
nonsteroidal antiinflammatory agents, antiestrogen compounds, and a variety of
other agents in small series. Imatinib mesylate appears to demonstrate inhibitory
activity against multiple class 3 receptor tyrosine kinases, including platelet-de-
rived growth factor receptor (PDGFR)- and PDGFR-, as well as c-kit.
METHODS. The authors performed immunohistochemical and qualitative real-time
polymerase chain reaction analysis on nine desmoid tumor specimens that dem-
onstrated consistent positivity for c-kit as well as PDGFR- and PDGFR-. At the
time of last follow-up, 2 patients had received therapy with imatinib mesylate at a
dose of 400 mg twice daily.
RESULTS. Both patients demonstrated ongoing radiographic and clinical responses
with a duration of 9 months and 11 months, respectively.
CONCLUSIONS. Imatinib mesylate has been reported to have activity against des-
moid tumor, most likely because of c-kit and PDGFR receptor tyrosine kinase
activity inhibition, and warrants further study. The relative novelty of this agent
and the lack of long-term toxicity data should prompt its use only in the salvage
setting in which established local and systemic approaches fail to control disease.
In addition, the use of imatinib mesylate in the treatment of this neoplasm
preferably should be in the context of a formal prospective clinical trial. Cancer
2002;95:2373–9. © 2002 American Cancer Society.
DOI 10.1002/cncr.11029
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Desmoid tumor, also known as aggressive fibromatosis, representsa rare monoclonal neoplasm arising from deep musculoaponeu-
rotic structures.1–3 Reported to affect approximately 2– 4 per million
persons annually, desmoid tumor may occur sporadically or in asso-
ciation with the familial adenomatous polyposis (FAP) syndrome and
Gardner syndrome.4 – 6 Women of childbearing age are reported to be
affected most often.7
To our knowledge the specific etiologic mechanisms that give rise
to this neoplasm are poorly understood. The observation of clonal
cytogenetics in both FAP-associated and sporadic desmoid tumor
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supports a genetic predisposition for the development
of this disease.2– 4 Prior trauma or surgery,8 –13 as well
as endogenous or exogenous estrogen exposure, also
appear to play a contributory role.7,8,14,15 Although the
overwhelming majority of FAP-associated diagnoses
occur in the abdomen or abdominal wall, approxi-
mately only 50% of the reported sporadic cases occur
in this anatomic location. The soft tissues of the shoul-
der, neck, and chest wall constitute the majority of the
remaining sites of occurrence, with the extremities
being involved in a minority of patients.14 Although
desmoid tumors do not demonstrate metastatic po-
tential, the morbidity that results from this disease
and its treatment cannot be understated. Local infil-
trative growth and tissue invasion can result in pain,
deformity, functional impairment, and death when
vital organs are involved.14,16,17 The attendant morbid-
ity and mortality from these tumors is highly site-
dependent. Intraabdominal desmoid infiltration of vi-
tal organs reportedly leads to a 10-year mortality rate
of approximately 37%.14 Mortality is rare among pa-
tients with extraabdominal desmoid tumors; however,
the disfigurement and loss of function that result from
tumor progression or its treatment is significant.
The delineation of optimal therapy for desmoid
tumor has been confounded by the rarity of the diag-
nosis, as well as a lack of randomized and prospective
direct comparisons of treatment approaches. Also
problematic is the inclusion in a majority of studies of
varied anatomic presentations, thereby limiting the
ability to draw definitive conclusions regarding effi-
cacy. Generally accepted rates of local recurrence after
surgical excision are approximately 30 –50%.16 –24 This
reflects the impact of tumor location and the ability of
the surgeon to achieve negative surgical margins. At
doses of 50 – 60 Gy, definitive radiotherapy has dem-
onstrated local control rates of 75% in cases in which
surgery is not feasible.19 Adjuvant radiotherapy has
been shown to reduce recurrence rates by as much as
50%, and may offset the negative prognostic impact of
positive surgical margins, allowing for a surgical ap-
proach that balances local control with a significant
impact on long-term function and morbidity.16
Despite having a relatively high local failure rate,
surgical resection of extraabdominal desmoid tumors,
with adjuvant radiotherapy for a positive surgical mar-
gin, remains the standard approach. Although primary
radiotherapy can produce local control rates that are
comparable to those achieved with surgery alone,25
the risk of secondary malignancy and the potential for
postradiation fibrosis make surgery the initial option
of choice if a negative surgical margin resection is
anticipated.
To our knowledge there are limited data with re-
gard to outcome in patients with recurrent desmoid
tumor. A minority of patients demonstrate durable
benefit from surgical excision of recurrent dis-
ease.11,24,26 –28 However, a significant proportion of pa-
tients will experience local recurrences that are not
amenable to surgical resection or radiotherapy. A va-
riety of systemic therapy approaches therefore have
become increasingly investigated and utilized. As is
the case with local therapies, the data for systemic
agents generally are limited to relatively small series
reports. Variable anatomic locations and patient treat-
ment history preclude comparisons between agents,
and the durability of responses is to our knowledge
underreported. It is important to note that there is
likely significant reporting bias that may serve to ex-
aggerate rates of success. Responses have been dem-
onstrated using a variety of nonsteroidal antiinflam-
matory agents (NSAIDs), of which sulindac has a
reported response rate of 50%.29 –32 This class of com-
pounds inhibits cyclooxogenase activity, prevents ac-
tivation of ornithine decarboxylase (ODC), and de-
creases intracellular levels of cyclic adenosine
monophosphate (cAMP). Reported response rates to
tamoxifen also approximate 50%. Antitumor activity
likely results from the blockade of estrogen-dependent
cellular proliferation, including the prevention of ODC
activation.10 Antagonistic effects on both platelet-de-
rived growth factor- (PDGF-) production and pros-
taglandin metabolism also may contribute to the effi-
cacy of this drug.31,33–37 Conventional cytotoxic
therapy also has demonstrated anecdotal success, oc-
casionally producing prolonged progression-free peri-
ods.11,26,35,38 – 44 In our experience, prolonged treat-
ment confers a proportionally longer progression-free
period; however, toxicity limits the duration and suc-
cess of this approach.
A variety of other agents also have been employed
in the treatment of desmoid tumor with variable suc-
cess, including interferon,45 ascorbic acid, theophyl-
line, chlorthiazide, megestrol, and other progesterone
formulations.13–15,20,26,31
Imatinib mesylate (Gleevec™; Novartis Pharma-
ceuticals, Hanover, NJ) represents a selective tyrosine
kinase inhibitor. In addition to the antagonistic action
against the dysregulated bcr-Abl fusion protein ob-
served in patients with chronic myelogenous leuke-
mia,46,47 imatinib mesylate also possesses inhibitory
activity against multiple class 3 receptor tyrosine ki-
nases (RTKs), including PDGFR- and PDGFR-, as
well as the c-kit subtype.46 This agent blocks ligand-
activated receptor phosphorylation and mitogen-acti-
vated kinase activation and proliferation, resulting in
the inhibition of cellular growth and proliferation.48
Inhibition of c-kit RTK activity is hypothesized to ac-
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count for the dramatic responses observed in the ma-
jority of patients with gastrointestinal stromal tumors
treated with imatinib mesylate).49 Inhibition of
PDGFR activity has produced dramatic cytoreduction
in a murine dermatofibrosarcoma protuberans model,50
and yielded clinical responses in this tumor subtype as
well.51
After internal review board approval, we per-
formed immunohistochemical (IHC) and qualitative
real-time polymerase chain reaction analysis of nine
desmoid tumor specimens. The results are summa-
rized in Table 1, and selective IHC specimens are
depicted in Figures 1–3. Figures 1–3 depict represen-
tative specimens, with IHC staining for PDGF-,
PDGF-, and c-kit, respectively.
Two patients (Patients 7 and 9) received therapy
with imatinab mesylate, and both demonstrated a re-
sponse.
Case Reports
Patient 1 was diagnosed with a desmoid tumor involv-
ing the distal right lower extremity at the age of 15
years. There was no personal or family history of FAP,
prior history of desmoid tumor, or features consistent
with Gardner syndrome. Initial therapy was com-
prised of low-dose oral etoposide and methotrexate,
despite which the patient experienced progressive dis-
ease. Partial amputation of the right forefoot and sev-
eral digits was performed. Over the ensuing 4-year
period, despite antiestrogen and nonsteroidal thera-
pies, the patient required multiple resections of non-
contiguous recurrent lesions involving the right calf
and thigh. Two of these surgical procedures were fol-
lowed by adjuvant radiotherapy for positive surgical
margins. The patient experienced significant func-
tional limitations of her right leg and gait as a result of
her treatments. Eight months after her last resection, a
14 cm  12 cm symptomatic desmoid tumor recurred
at approximately the right sciatic nerve in the mid-
FIGURE 1. Immunohistochemical staining for platelet-derived growth factor
receptor- in a desmoid tumor specimen. Anti-PDGFR- (Santa Cruz Biotech,
Santa Cruz, CA; 1:200); avidin-biotin-peroxidase complex. Hematoxylin; original
magnification  400.
TABLE 1
Immunohistochemical/RT-PCR Characteristics of Nine Desmoid Tumors
Patient no. Location Status c-Kit PDGFR- PDGFR- PDGF- PDGF-
1 Intraabdominal Primary    NA NA
2 Abdominal wall Primary    NA NA
3 Abdominal wall Primary    NA NA
4 Left arm Primary    NA NA
5 Abdominal wall Primary    NA NA
6 Right hip Recurrent    NA NA
7 Right thigh Recurrent     
8 Pelvic Recurrent     
9 Left chest wall Recurrent     
RT-PCR: reverse transcriptase-polymerase chain reaction; PDGFR: platelet-derived growth factor receptor; PDGF: platelet-derived growth factor; : positive; NA: not available.
Response of Desmoid Tumors to Imatinib Mesylate/Mace et al. 2375
thigh. A second lesion measuring 5 cm  6 cm was
noted in the soft tissues posterior to the right femoral
neck, and was found to extend proximally into the
distal right hemipelvis on magnetic resonance imag-
ing. The patient sought consultation at the Sarcoma
clinic at the University of Michigan Comprehensive
Cancer Center in May 2001 after a hindquarter ampu-
tation was suggested. Concern regarding morbidity, as
well as the ability of an amputation to control the
entirety of her disease, resulted in the consideration of
systemic therapy with imatinib mesylate. Therapy was
initiated in June 2001. Figure 4 depicts the lesions
prior to therapy. After 2 months of treatment at a dose
of 400 mg twice daily (Fig. 5), significant improvement
was noted. This trend continued over the next 6
months, with an overall approximate 50% reduction in
the size of the tumor masses. At the time of last follow-
up, the patient continued to demonstrate an ongoing
response to therapy, with concomitant improvement
in referable symptoms. Therapy has been well toler-
ated and has continued without any reported compli-
cations.
Patient 2 was a 39-year-old man who experienced
extensive burns to his anterior trunk during child-
hood. He was diagnosed with a desmoid tumor involv-
ing the left pectoralis musculature in 1996, for which
he underwent a radical mastectomy. Approximately 1
year later a symptomatic 12 cm  8 cm local recur-
rence was noted on magnetic resonance imaging.
Therapy with NSAIDs and tamoxifen proved ineffec-
tive, and low-dose oral etoposide and methotrexate
was initiated. The patient demonstrated a partial re-
sponse to chemotherapy that lasted for 34 months,
after which worsening symptoms prompted the per-
formance of magnetic resonance imaging. This re-
vealed progression of the desmoid tumor of the left
chest wall, and the patient was offered aggressive re-
FIGURE 2. Immunohistochemical staining for platelet-derived growth factor
receptor- in a desmoid tumor specimen. Anti-PDGFR- (Santa Cruz Biotech,
1:200); avidin-biotin-peroxidase complex. Hematoxylin; original magnification
 400.
FIGURE 3. Immunohistochemical staining for c-kit in a desmoid tumor
specimen. Anti c-kit (Dako Corp., Carpinteria, CA; 1:100); avidin-biotin-perox-
idase complex. Hematoxylin; original magnification  400.
2376 CANCER December 1, 2002 / Volume 95 / Number 11
section, which would likely entail a forequarter ampu-
tation. Once again, concern regarding the morbidity
and efficacy of this approach was raised, and imatinib
mesylate at a dose of 400 mg twice daily was initiated
in August 2001. At the time of last follow-up, the
patient’s tumor was stable with respect to size; how-
ever, it demonstrated ongoing significant reductions
in internal density and enhancement since therapy
was initiated. The patient likewise was experiencing
continued improvement of symptoms.
FIGURE 4. Desmoid lesions (A, B) in Patient 1 prior to therapy.
FIGURE 5. Desmoid lesions (A, B) in Patient 1 after 2 months of therapy.
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DISCUSSION
Desmoid tumor represents a therapeutic challenge
that requires multidisciplinary collaboration from sur-
gical, medical, and radiation oncologists. As a result of
balancing local control with posttreatment function
and morbidity, a significant number of patients will
develop a disease recurrence despite surgery and ra-
diotherapy. Although a reasonable proportion of pa-
tients will respond to “frontline” systemic therapies,
including antiestrogen compounds and NSAIDs,
many will develop progressive disease despite such
treatments. Conventional chemotherapy, typically ad-
ministered in low doses over a prolonged period of
time, has demonstrated encouraging results; however,
the duration of treatment inherently is limited by cu-
mulative toxicity. Based on the IHC and reverse tran-
scriptase-polymerase chain reaction characteristics of
nine desmoid tumors, two young patients with heavily
pretreated and recurrent desmoid tumors were
treated with imatinib mesylate in an attempt to avoid
the morbidity associated with amputation. Both pa-
tients were reported to have tolerated treatment,
which at the time of last follow-up was ongoing at 9
months and 11 months, respectively. Both patients
experienced radiographic responses with associated
improvement in symptoms and function.
The use of imatinib mesylate in the treatment of
desmoid tumors has produced encouraging prelimi-
nary results. However, the relative novelty of this
agent and the lack of long-term toxicity data should
prompt its use only in the salvage setting in which
surgery, radiotherapy, and established systemic agents
have failed to control disease. In addition, the use of
imatinib mesylate in the treatment of this neoplasm
preferably should be in the context of a formal pro-
spective clinical trial. The North American Treatment
Consortium of the Connective Tissue Oncology Soci-
ety has initiated such a trial. Nonetheless, we conclude
that imatinib mesylate has activity against desmoid
tumors, most likely because of c-kit and PDGFR RTK
activity inhibition, and therefore warrants further
study in the treatment of this challenging and difficult
disease.
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